Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial

Background Studying the differential impact of aspirin and other nonsteroidal anti‐inflammatory drugs across the stages of colorectal neoplasia from early adenoma to cancer is critical for understanding the benefits of these widely used drugs. Methods With 13 years of follow‐up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population‐based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. With multivariable‐adjusted models, odds ratio (ORs) and 95% confidence intervals (CIs) for adenoma incidence and recurrence and hazard ratios (HRs) and 95% CIs for incident CRC were determined. Results The authors observed a significantly reduced risk of incident adenoma with ibuprofen use (≥30 vs